Key points are not available for this paper at this time.
= 0.013). In the analysis of different treatment regimens in the immunotherapy rechallenge group, immune checkpoint inhibitors (ICIs) + antiangiogenic therapy achieved the best PFS. These findings elucidate the role of ICI-based treatment strategies in patients with advanced NSCLC and are expected to supplement lung cancer immunotherapy guidelines.
Li et al. (2026) studied this question.